Pashootan P, Ploussard G, Cocaul A, de Gouvello A, Desgrandchamps F
BJU Int. In press. http://dx.doi.org/10.1111/bju.12931
Experts’ summary:
Pashootan et al, in an observational study, evaluated the relationship between metabolic syndrome (MS) and lower urinary tract symptoms (LUTS) in a large cohort of men aged >55 yr in France. Overall, 4666 male patients were enrolled by 379 general practitioners randomly selected in France. LUTS were evaluated using the International Prostatic Symptoms Score (IPSS), and the Adult Treatment Panel III criteria were used to define the presence of MS. The presence of MS was significantly associated with LUTS severity in terms of overall IPSS (odds ratio [OR]: 1.56; 95% confidence interval [CI], 1.35–1.80;p < 0.001). Voiding and storage scores were increased by 67% and 72%, respectively, in men with MS compared with controls. The risk of being treated for LUTS depended on the number of individual MS components. An OR of 1.5 or 3.5 was observed when 2 or 5 components, respectively, were present (p < 0.001).
Experts’ comments:
MS describes the combination of several metabolic abnormalities and is directly associated with an increase in the risk of coronary heart disease. Recently, epidemiologic and clinical studies in American and Asian populations have provided emerging evidence of a possible role for MS and its components in the occurrence and progression of LUTS[1] and [2]. In Europe, we recently observed that MS is a frequently occurring (24%) condition in patients with LUTS, and its presence increased the risk of having an IPSS storage subscore ≥4 in patients with LUTS by about 80% (OR: 1.78; 95% CI, 1.045–3.042;p = 0.03) [3] . Although the study presented by Pashootan et al confirmed these observations in Western Europe and further increased the evidence of the relationship between MS and LUTS, the study did not investigate the biological mechanism beyond this association. This study also established in a real-life setting that MS is a frequently occurring condition in urologic patients, and the authors proposed that MS evaluation should be part of the standard assessment of male patients with LUTS as well as a new domain in clinical and basic research.
At this time, it is reasonable to suggest that patients with LUTS and MS should exercise regularly, eat a balanced diet, and maintain a healthy weight to prevent or reverse MS. Whether or not this advice will improve patients’ LUTS and progression of benign prostatic enlargement is still a matter or debate, although it will certainly improve heart health and reduce the risk of cardiovascular disease, the most common cause of male mortality. In our opinion, the truly important questions arising from this study are whether the presence of MS should change LUTS assessment and treatment and what the different factors of MS are, such as patient lifestyle including physical activity, abdominal obesity, and multiple serum hormone alterations including testosterone and insulin resistance, that are responsible for the observed association between LUTS and MS. In summary, we would like to accelerate further research on this topic to explore the complex relationship between LUTS and MS.
Pashootan P, Ploussard G, Cocaul A, de Gouvello A, Desgrandchamps F
BJU Int. In press. http://dx.doi.org/10.1111/bju.12931
Experts’ summary:
Pashootan et al, in an observational study, evaluated the relationship between metabolic syndrome (MS) and lower urinary tract symptoms (LUTS) in a large cohort of men aged >55 yr in France. Overall, 4666 male patients were enrolled by 379 general practitioners randomly selected in France. LUTS were evaluated using the International Prostatic Symptoms Score (IPSS), and the Adult Treatment Panel III criteria were used to define the presence of MS. The presence of MS was significantly associated with LUTS severity in terms of overall IPSS (odds ratio [OR]: 1.56; 95% confidence interval [CI], 1.35–1.80;p < 0.001). Voiding and storage scores were increased by 67% and 72%, respectively, in men with MS compared with controls. The risk of being treated for LUTS depended on the number of individual MS components. An OR of 1.5 or 3.5 was observed when 2 or 5 components, respectively, were present (p < 0.001).
Experts’ comments:
MS describes the combination of several metabolic abnormalities and is directly associated with an increase in the risk of coronary heart disease. Recently, epidemiologic and clinical studies in American and Asian populations have provided emerging evidence of a possible role for MS and its components in the occurrence and progression of LUTS[1] and [2]. In Europe, we recently observed that MS is a frequently occurring (24%) condition in patients with LUTS, and its presence increased the risk of having an IPSS storage subscore ≥4 in patients with LUTS by about 80% (OR: 1.78; 95% CI, 1.045–3.042;p = 0.03) [3] . Although the study presented by Pashootan et al confirmed these observations in Western Europe and further increased the evidence of the relationship between MS and LUTS, the study did not investigate the biological mechanism beyond this association. This study also established in a real-life setting that MS is a frequently occurring condition in urologic patients, and the authors proposed that MS evaluation should be part of the standard assessment of male patients with LUTS as well as a new domain in clinical and basic research.
At this time, it is reasonable to suggest that patients with LUTS and MS should exercise regularly, eat a balanced diet, and maintain a healthy weight to prevent or reverse MS. Whether or not this advice will improve patients’ LUTS and progression of benign prostatic enlargement is still a matter or debate, although it will certainly improve heart health and reduce the risk of cardiovascular disease, the most common cause of male mortality. In our opinion, the truly important questions arising from this study are whether the presence of MS should change LUTS assessment and treatment and what the different factors of MS are, such as patient lifestyle including physical activity, abdominal obesity, and multiple serum hormone alterations including testosterone and insulin resistance, that are responsible for the observed association between LUTS and MS. In summary, we would like to accelerate further research on this topic to explore the complex relationship between LUTS and MS.
Pashootan P, Ploussard G, Cocaul A, de Gouvello A, Desgrandchamps F
BJU Int. In press. http://dx.doi.org/10.1111/bju.12931
Experts’ summary:
Pashootan et al, in an observational study, evaluated the relationship between metabolic syndrome (MS) and lower urinary tract symptoms (LUTS) in a large cohort of men aged >55 yr in France. Overall, 4666 male patients were enrolled by 379 general practitioners randomly selected in France. LUTS were evaluated using the International Prostatic Symptoms Score (IPSS), and the Adult Treatment Panel III criteria were used to define the presence of MS. The presence of MS was significantly associated with LUTS severity in terms of overall IPSS (odds ratio [OR]: 1.56; 95% confidence interval [CI], 1.35–1.80;p < 0.001). Voiding and storage scores were increased by 67% and 72%, respectively, in men with MS compared with controls. The risk of being treated for LUTS depended on the number of individual MS components. An OR of 1.5 or 3.5 was observed when 2 or 5 components, respectively, were present (p < 0.001).
Experts’ comments:
MS describes the combination of several metabolic abnormalities and is directly associated with an increase in the risk of coronary heart disease. Recently, epidemiologic and clinical studies in American and Asian populations have provided emerging evidence of a possible role for MS and its components in the occurrence and progression of LUTS[1] and [2]. In Europe, we recently observed that MS is a frequently occurring (24%) condition in patients with LUTS, and its presence increased the risk of having an IPSS storage subscore ≥4 in patients with LUTS by about 80% (OR: 1.78; 95% CI, 1.045–3.042;p = 0.03) [3] . Although the study presented by Pashootan et al confirmed these observations in Western Europe and further increased the evidence of the relationship between MS and LUTS, the study did not investigate the biological mechanism beyond this association. This study also established in a real-life setting that MS is a frequently occurring condition in urologic patients, and the authors proposed that MS evaluation should be part of the standard assessment of male patients with LUTS as well as a new domain in clinical and basic research.
At this time, it is reasonable to suggest that patients with LUTS and MS should exercise regularly, eat a balanced diet, and maintain a healthy weight to prevent or reverse MS. Whether or not this advice will improve patients’ LUTS and progression of benign prostatic enlargement is still a matter or debate, although it will certainly improve heart health and reduce the risk of cardiovascular disease, the most common cause of male mortality. In our opinion, the truly important questions arising from this study are whether the presence of MS should change LUTS assessment and treatment and what the different factors of MS are, such as patient lifestyle including physical activity, abdominal obesity, and multiple serum hormone alterations including testosterone and insulin resistance, that are responsible for the observed association between LUTS and MS. In summary, we would like to accelerate further research on this topic to explore the complex relationship between LUTS and MS.
Pashootan P, Ploussard G, Cocaul A, de Gouvello A, Desgrandchamps F
BJU Int. In press. http://dx.doi.org/10.1111/bju.12931
Experts’ summary:
Pashootan et al, in an observational study, evaluated the relationship between metabolic syndrome (MS) and lower urinary tract symptoms (LUTS) in a large cohort of men aged >55 yr in France. Overall, 4666 male patients were enrolled by 379 general practitioners randomly selected in France. LUTS were evaluated using the International Prostatic Symptoms Score (IPSS), and the Adult Treatment Panel III criteria were used to define the presence of MS. The presence of MS was significantly associated with LUTS severity in terms of overall IPSS (odds ratio [OR]: 1.56; 95% confidence interval [CI], 1.35–1.80;p < 0.001). Voiding and storage scores were increased by 67% and 72%, respectively, in men with MS compared with controls. The risk of being treated for LUTS depended on the number of individual MS components. An OR of 1.5 or 3.5 was observed when 2 or 5 components, respectively, were present (p < 0.001).
Experts’ comments:
MS describes the combination of several metabolic abnormalities and is directly associated with an increase in the risk of coronary heart disease. Recently, epidemiologic and clinical studies in American and Asian populations have provided emerging evidence of a possible role for MS and its components in the occurrence and progression of LUTS[1] and [2]. In Europe, we recently observed that MS is a frequently occurring (24%) condition in patients with LUTS, and its presence increased the risk of having an IPSS storage subscore ≥4 in patients with LUTS by about 80% (OR: 1.78; 95% CI, 1.045–3.042;p = 0.03) [3] . Although the study presented by Pashootan et al confirmed these observations in Western Europe and further increased the evidence of the relationship between MS and LUTS, the study did not investigate the biological mechanism beyond this association. This study also established in a real-life setting that MS is a frequently occurring condition in urologic patients, and the authors proposed that MS evaluation should be part of the standard assessment of male patients with LUTS as well as a new domain in clinical and basic research.
At this time, it is reasonable to suggest that patients with LUTS and MS should exercise regularly, eat a balanced diet, and maintain a healthy weight to prevent or reverse MS. Whether or not this advice will improve patients’ LUTS and progression of benign prostatic enlargement is still a matter or debate, although it will certainly improve heart health and reduce the risk of cardiovascular disease, the most common cause of male mortality. In our opinion, the truly important questions arising from this study are whether the presence of MS should change LUTS assessment and treatment and what the different factors of MS are, such as patient lifestyle including physical activity, abdominal obesity, and multiple serum hormone alterations including testosterone and insulin resistance, that are responsible for the observed association between LUTS and MS. In summary, we would like to accelerate further research on this topic to explore the complex relationship between LUTS and MS.
Pashootan P, Ploussard G, Cocaul A, de Gouvello A, Desgrandchamps F
BJU Int. In press. http://dx.doi.org/10.1111/bju.12931
Experts’ summary:
Pashootan et al, in an observational study, evaluated the relationship between metabolic syndrome (MS) and lower urinary tract symptoms (LUTS) in a large cohort of men aged >55 yr in France. Overall, 4666 male patients were enrolled by 379 general practitioners randomly selected in France. LUTS were evaluated using the International Prostatic Symptoms Score (IPSS), and the Adult Treatment Panel III criteria were used to define the presence of MS. The presence of MS was significantly associated with LUTS severity in terms of overall IPSS (odds ratio [OR]: 1.56; 95% confidence interval [CI], 1.35–1.80;p < 0.001). Voiding and storage scores were increased by 67% and 72%, respectively, in men with MS compared with controls. The risk of being treated for LUTS depended on the number of individual MS components. An OR of 1.5 or 3.5 was observed when 2 or 5 components, respectively, were present (p < 0.001).
Experts’ comments:
MS describes the combination of several metabolic abnormalities and is directly associated with an increase in the risk of coronary heart disease. Recently, epidemiologic and clinical studies in American and Asian populations have provided emerging evidence of a possible role for MS and its components in the occurrence and progression of LUTS[1] and [2]. In Europe, we recently observed that MS is a frequently occurring (24%) condition in patients with LUTS, and its presence increased the risk of having an IPSS storage subscore ≥4 in patients with LUTS by about 80% (OR: 1.78; 95% CI, 1.045–3.042;p = 0.03) [3] . Although the study presented by Pashootan et al confirmed these observations in Western Europe and further increased the evidence of the relationship between MS and LUTS, the study did not investigate the biological mechanism beyond this association. This study also established in a real-life setting that MS is a frequently occurring condition in urologic patients, and the authors proposed that MS evaluation should be part of the standard assessment of male patients with LUTS as well as a new domain in clinical and basic research.
At this time, it is reasonable to suggest that patients with LUTS and MS should exercise regularly, eat a balanced diet, and maintain a healthy weight to prevent or reverse MS. Whether or not this advice will improve patients’ LUTS and progression of benign prostatic enlargement is still a matter or debate, although it will certainly improve heart health and reduce the risk of cardiovascular disease, the most common cause of male mortality. In our opinion, the truly important questions arising from this study are whether the presence of MS should change LUTS assessment and treatment and what the different factors of MS are, such as patient lifestyle including physical activity, abdominal obesity, and multiple serum hormone alterations including testosterone and insulin resistance, that are responsible for the observed association between LUTS and MS. In summary, we would like to accelerate further research on this topic to explore the complex relationship between LUTS and MS.
Pashootan P, Ploussard G, Cocaul A, de Gouvello A, Desgrandchamps F
BJU Int. In press. http://dx.doi.org/10.1111/bju.12931
Experts’ summary:
Pashootan et al, in an observational study, evaluated the relationship between metabolic syndrome (MS) and lower urinary tract symptoms (LUTS) in a large cohort of men aged >55 yr in France. Overall, 4666 male patients were enrolled by 379 general practitioners randomly selected in France. LUTS were evaluated using the International Prostatic Symptoms Score (IPSS), and the Adult Treatment Panel III criteria were used to define the presence of MS. The presence of MS was significantly associated with LUTS severity in terms of overall IPSS (odds ratio [OR]: 1.56; 95% confidence interval [CI], 1.35–1.80;p < 0.001). Voiding and storage scores were increased by 67% and 72%, respectively, in men with MS compared with controls. The risk of being treated for LUTS depended on the number of individual MS components. An OR of 1.5 or 3.5 was observed when 2 or 5 components, respectively, were present (p < 0.001).
Experts’ comments:
MS describes the combination of several metabolic abnormalities and is directly associated with an increase in the risk of coronary heart disease. Recently, epidemiologic and clinical studies in American and Asian populations have provided emerging evidence of a possible role for MS and its components in the occurrence and progression of LUTS[1] and [2]. In Europe, we recently observed that MS is a frequently occurring (24%) condition in patients with LUTS, and its presence increased the risk of having an IPSS storage subscore ≥4 in patients with LUTS by about 80% (OR: 1.78; 95% CI, 1.045–3.042;p = 0.03) [3] . Although the study presented by Pashootan et al confirmed these observations in Western Europe and further increased the evidence of the relationship between MS and LUTS, the study did not investigate the biological mechanism beyond this association. This study also established in a real-life setting that MS is a frequently occurring condition in urologic patients, and the authors proposed that MS evaluation should be part of the standard assessment of male patients with LUTS as well as a new domain in clinical and basic research.
At this time, it is reasonable to suggest that patients with LUTS and MS should exercise regularly, eat a balanced diet, and maintain a healthy weight to prevent or reverse MS. Whether or not this advice will improve patients’ LUTS and progression of benign prostatic enlargement is still a matter or debate, although it will certainly improve heart health and reduce the risk of cardiovascular disease, the most common cause of male mortality. In our opinion, the truly important questions arising from this study are whether the presence of MS should change LUTS assessment and treatment and what the different factors of MS are, such as patient lifestyle including physical activity, abdominal obesity, and multiple serum hormone alterations including testosterone and insulin resistance, that are responsible for the observed association between LUTS and MS. In summary, we would like to accelerate further research on this topic to explore the complex relationship between LUTS and MS.
Pashootan P, Ploussard G, Cocaul A, de Gouvello A, Desgrandchamps F
BJU Int. In press. http://dx.doi.org/10.1111/bju.12931
Experts’ summary:
Pashootan et al, in an observational study, evaluated the relationship between metabolic syndrome (MS) and lower urinary tract symptoms (LUTS) in a large cohort of men aged >55 yr in France. Overall, 4666 male patients were enrolled by 379 general practitioners randomly selected in France. LUTS were evaluated using the International Prostatic Symptoms Score (IPSS), and the Adult Treatment Panel III criteria were used to define the presence of MS. The presence of MS was significantly associated with LUTS severity in terms of overall IPSS (odds ratio [OR]: 1.56; 95% confidence interval [CI], 1.35–1.80;p < 0.001). Voiding and storage scores were increased by 67% and 72%, respectively, in men with MS compared with controls. The risk of being treated for LUTS depended on the number of individual MS components. An OR of 1.5 or 3.5 was observed when 2 or 5 components, respectively, were present (p < 0.001).
Experts’ comments:
MS describes the combination of several metabolic abnormalities and is directly associated with an increase in the risk of coronary heart disease. Recently, epidemiologic and clinical studies in American and Asian populations have provided emerging evidence of a possible role for MS and its components in the occurrence and progression of LUTS[1] and [2]. In Europe, we recently observed that MS is a frequently occurring (24%) condition in patients with LUTS, and its presence increased the risk of having an IPSS storage subscore ≥4 in patients with LUTS by about 80% (OR: 1.78; 95% CI, 1.045–3.042;p = 0.03) [3] . Although the study presented by Pashootan et al confirmed these observations in Western Europe and further increased the evidence of the relationship between MS and LUTS, the study did not investigate the biological mechanism beyond this association. This study also established in a real-life setting that MS is a frequently occurring condition in urologic patients, and the authors proposed that MS evaluation should be part of the standard assessment of male patients with LUTS as well as a new domain in clinical and basic research.
At this time, it is reasonable to suggest that patients with LUTS and MS should exercise regularly, eat a balanced diet, and maintain a healthy weight to prevent or reverse MS. Whether or not this advice will improve patients’ LUTS and progression of benign prostatic enlargement is still a matter or debate, although it will certainly improve heart health and reduce the risk of cardiovascular disease, the most common cause of male mortality. In our opinion, the truly important questions arising from this study are whether the presence of MS should change LUTS assessment and treatment and what the different factors of MS are, such as patient lifestyle including physical activity, abdominal obesity, and multiple serum hormone alterations including testosterone and insulin resistance, that are responsible for the observed association between LUTS and MS. In summary, we would like to accelerate further research on this topic to explore the complex relationship between LUTS and MS.
Pashootan P, Ploussard G, Cocaul A, de Gouvello A, Desgrandchamps F
BJU Int. In press. http://dx.doi.org/10.1111/bju.12931
Experts’ summary:
Pashootan et al, in an observational study, evaluated the relationship between metabolic syndrome (MS) and lower urinary tract symptoms (LUTS) in a large cohort of men aged >55 yr in France. Overall, 4666 male patients were enrolled by 379 general practitioners randomly selected in France. LUTS were evaluated using the International Prostatic Symptoms Score (IPSS), and the Adult Treatment Panel III criteria were used to define the presence of MS. The presence of MS was significantly associated with LUTS severity in terms of overall IPSS (odds ratio [OR]: 1.56; 95% confidence interval [CI], 1.35–1.80;p < 0.001). Voiding and storage scores were increased by 67% and 72%, respectively, in men with MS compared with controls. The risk of being treated for LUTS depended on the number of individual MS components. An OR of 1.5 or 3.5 was observed when 2 or 5 components, respectively, were present (p < 0.001).
Experts’ comments:
MS describes the combination of several metabolic abnormalities and is directly associated with an increase in the risk of coronary heart disease. Recently, epidemiologic and clinical studies in American and Asian populations have provided emerging evidence of a possible role for MS and its components in the occurrence and progression of LUTS[1] and [2]. In Europe, we recently observed that MS is a frequently occurring (24%) condition in patients with LUTS, and its presence increased the risk of having an IPSS storage subscore ≥4 in patients with LUTS by about 80% (OR: 1.78; 95% CI, 1.045–3.042;p = 0.03) [3] . Although the study presented by Pashootan et al confirmed these observations in Western Europe and further increased the evidence of the relationship between MS and LUTS, the study did not investigate the biological mechanism beyond this association. This study also established in a real-life setting that MS is a frequently occurring condition in urologic patients, and the authors proposed that MS evaluation should be part of the standard assessment of male patients with LUTS as well as a new domain in clinical and basic research.
At this time, it is reasonable to suggest that patients with LUTS and MS should exercise regularly, eat a balanced diet, and maintain a healthy weight to prevent or reverse MS. Whether or not this advice will improve patients’ LUTS and progression of benign prostatic enlargement is still a matter or debate, although it will certainly improve heart health and reduce the risk of cardiovascular disease, the most common cause of male mortality. In our opinion, the truly important questions arising from this study are whether the presence of MS should change LUTS assessment and treatment and what the different factors of MS are, such as patient lifestyle including physical activity, abdominal obesity, and multiple serum hormone alterations including testosterone and insulin resistance, that are responsible for the observed association between LUTS and MS. In summary, we would like to accelerate further research on this topic to explore the complex relationship between LUTS and MS.
Pashootan P, Ploussard G, Cocaul A, de Gouvello A, Desgrandchamps F
BJU Int. In press. http://dx.doi.org/10.1111/bju.12931
Experts’ summary:
Pashootan et al, in an observational study, evaluated the relationship between metabolic syndrome (MS) and lower urinary tract symptoms (LUTS) in a large cohort of men aged >55 yr in France. Overall, 4666 male patients were enrolled by 379 general practitioners randomly selected in France. LUTS were evaluated using the International Prostatic Symptoms Score (IPSS), and the Adult Treatment Panel III criteria were used to define the presence of MS. The presence of MS was significantly associated with LUTS severity in terms of overall IPSS (odds ratio [OR]: 1.56; 95% confidence interval [CI], 1.35–1.80;p < 0.001). Voiding and storage scores were increased by 67% and 72%, respectively, in men with MS compared with controls. The risk of being treated for LUTS depended on the number of individual MS components. An OR of 1.5 or 3.5 was observed when 2 or 5 components, respectively, were present (p < 0.001).
Experts’ comments:
MS describes the combination of several metabolic abnormalities and is directly associated with an increase in the risk of coronary heart disease. Recently, epidemiologic and clinical studies in American and Asian populations have provided emerging evidence of a possible role for MS and its components in the occurrence and progression of LUTS[1] and [2]. In Europe, we recently observed that MS is a frequently occurring (24%) condition in patients with LUTS, and its presence increased the risk of having an IPSS storage subscore ≥4 in patients with LUTS by about 80% (OR: 1.78; 95% CI, 1.045–3.042;p = 0.03) [3] . Although the study presented by Pashootan et al confirmed these observations in Western Europe and further increased the evidence of the relationship between MS and LUTS, the study did not investigate the biological mechanism beyond this association. This study also established in a real-life setting that MS is a frequently occurring condition in urologic patients, and the authors proposed that MS evaluation should be part of the standard assessment of male patients with LUTS as well as a new domain in clinical and basic research.
At this time, it is reasonable to suggest that patients with LUTS and MS should exercise regularly, eat a balanced diet, and maintain a healthy weight to prevent or reverse MS. Whether or not this advice will improve patients’ LUTS and progression of benign prostatic enlargement is still a matter or debate, although it will certainly improve heart health and reduce the risk of cardiovascular disease, the most common cause of male mortality. In our opinion, the truly important questions arising from this study are whether the presence of MS should change LUTS assessment and treatment and what the different factors of MS are, such as patient lifestyle including physical activity, abdominal obesity, and multiple serum hormone alterations including testosterone and insulin resistance, that are responsible for the observed association between LUTS and MS. In summary, we would like to accelerate further research on this topic to explore the complex relationship between LUTS and MS.
Pashootan P, Ploussard G, Cocaul A, de Gouvello A, Desgrandchamps F
BJU Int. In press. http://dx.doi.org/10.1111/bju.12931
Experts’ summary:
Pashootan et al, in an observational study, evaluated the relationship between metabolic syndrome (MS) and lower urinary tract symptoms (LUTS) in a large cohort of men aged >55 yr in France. Overall, 4666 male patients were enrolled by 379 general practitioners randomly selected in France. LUTS were evaluated using the International Prostatic Symptoms Score (IPSS), and the Adult Treatment Panel III criteria were used to define the presence of MS. The presence of MS was significantly associated with LUTS severity in terms of overall IPSS (odds ratio [OR]: 1.56; 95% confidence interval [CI], 1.35–1.80;p < 0.001). Voiding and storage scores were increased by 67% and 72%, respectively, in men with MS compared with controls. The risk of being treated for LUTS depended on the number of individual MS components. An OR of 1.5 or 3.5 was observed when 2 or 5 components, respectively, were present (p < 0.001).
Experts’ comments:
MS describes the combination of several metabolic abnormalities and is directly associated with an increase in the risk of coronary heart disease. Recently, epidemiologic and clinical studies in American and Asian populations have provided emerging evidence of a possible role for MS and its components in the occurrence and progression of LUTS[1] and [2]. In Europe, we recently observed that MS is a frequently occurring (24%) condition in patients with LUTS, and its presence increased the risk of having an IPSS storage subscore ≥4 in patients with LUTS by about 80% (OR: 1.78; 95% CI, 1.045–3.042;p = 0.03) [3] . Although the study presented by Pashootan et al confirmed these observations in Western Europe and further increased the evidence of the relationship between MS and LUTS, the study did not investigate the biological mechanism beyond this association. This study also established in a real-life setting that MS is a frequently occurring condition in urologic patients, and the authors proposed that MS evaluation should be part of the standard assessment of male patients with LUTS as well as a new domain in clinical and basic research.
At this time, it is reasonable to suggest that patients with LUTS and MS should exercise regularly, eat a balanced diet, and maintain a healthy weight to prevent or reverse MS. Whether or not this advice will improve patients’ LUTS and progression of benign prostatic enlargement is still a matter or debate, although it will certainly improve heart health and reduce the risk of cardiovascular disease, the most common cause of male mortality. In our opinion, the truly important questions arising from this study are whether the presence of MS should change LUTS assessment and treatment and what the different factors of MS are, such as patient lifestyle including physical activity, abdominal obesity, and multiple serum hormone alterations including testosterone and insulin resistance, that are responsible for the observed association between LUTS and MS. In summary, we would like to accelerate further research on this topic to explore the complex relationship between LUTS and MS.
Pashootan P, Ploussard G, Cocaul A, de Gouvello A, Desgrandchamps F
BJU Int. In press. http://dx.doi.org/10.1111/bju.12931
Experts’ summary:
Pashootan et al, in an observational study, evaluated the relationship between metabolic syndrome (MS) and lower urinary tract symptoms (LUTS) in a large cohort of men aged >55 yr in France. Overall, 4666 male patients were enrolled by 379 general practitioners randomly selected in France. LUTS were evaluated using the International Prostatic Symptoms Score (IPSS), and the Adult Treatment Panel III criteria were used to define the presence of MS. The presence of MS was significantly associated with LUTS severity in terms of overall IPSS (odds ratio [OR]: 1.56; 95% confidence interval [CI], 1.35–1.80;p < 0.001). Voiding and storage scores were increased by 67% and 72%, respectively, in men with MS compared with controls. The risk of being treated for LUTS depended on the number of individual MS components. An OR of 1.5 or 3.5 was observed when 2 or 5 components, respectively, were present (p < 0.001).
Experts’ comments:
MS describes the combination of several metabolic abnormalities and is directly associated with an increase in the risk of coronary heart disease. Recently, epidemiologic and clinical studies in American and Asian populations have provided emerging evidence of a possible role for MS and its components in the occurrence and progression of LUTS[1] and [2]. In Europe, we recently observed that MS is a frequently occurring (24%) condition in patients with LUTS, and its presence increased the risk of having an IPSS storage subscore ≥4 in patients with LUTS by about 80% (OR: 1.78; 95% CI, 1.045–3.042;p = 0.03) [3] . Although the study presented by Pashootan et al confirmed these observations in Western Europe and further increased the evidence of the relationship between MS and LUTS, the study did not investigate the biological mechanism beyond this association. This study also established in a real-life setting that MS is a frequently occurring condition in urologic patients, and the authors proposed that MS evaluation should be part of the standard assessment of male patients with LUTS as well as a new domain in clinical and basic research.
At this time, it is reasonable to suggest that patients with LUTS and MS should exercise regularly, eat a balanced diet, and maintain a healthy weight to prevent or reverse MS. Whether or not this advice will improve patients’ LUTS and progression of benign prostatic enlargement is still a matter or debate, although it will certainly improve heart health and reduce the risk of cardiovascular disease, the most common cause of male mortality. In our opinion, the truly important questions arising from this study are whether the presence of MS should change LUTS assessment and treatment and what the different factors of MS are, such as patient lifestyle including physical activity, abdominal obesity, and multiple serum hormone alterations including testosterone and insulin resistance, that are responsible for the observed association between LUTS and MS. In summary, we would like to accelerate further research on this topic to explore the complex relationship between LUTS and MS.
Pashootan P, Ploussard G, Cocaul A, de Gouvello A, Desgrandchamps F
BJU Int. In press. http://dx.doi.org/10.1111/bju.12931
Experts’ summary:
Pashootan et al, in an observational study, evaluated the relationship between metabolic syndrome (MS) and lower urinary tract symptoms (LUTS) in a large cohort of men aged >55 yr in France. Overall, 4666 male patients were enrolled by 379 general practitioners randomly selected in France. LUTS were evaluated using the International Prostatic Symptoms Score (IPSS), and the Adult Treatment Panel III criteria were used to define the presence of MS. The presence of MS was significantly associated with LUTS severity in terms of overall IPSS (odds ratio [OR]: 1.56; 95% confidence interval [CI], 1.35–1.80;p < 0.001). Voiding and storage scores were increased by 67% and 72%, respectively, in men with MS compared with controls. The risk of being treated for LUTS depended on the number of individual MS components. An OR of 1.5 or 3.5 was observed when 2 or 5 components, respectively, were present (p < 0.001).
Experts’ comments:
MS describes the combination of several metabolic abnormalities and is directly associated with an increase in the risk of coronary heart disease. Recently, epidemiologic and clinical studies in American and Asian populations have provided emerging evidence of a possible role for MS and its components in the occurrence and progression of LUTS[1] and [2]. In Europe, we recently observed that MS is a frequently occurring (24%) condition in patients with LUTS, and its presence increased the risk of having an IPSS storage subscore ≥4 in patients with LUTS by about 80% (OR: 1.78; 95% CI, 1.045–3.042;p = 0.03) [3] . Although the study presented by Pashootan et al confirmed these observations in Western Europe and further increased the evidence of the relationship between MS and LUTS, the study did not investigate the biological mechanism beyond this association. This study also established in a real-life setting that MS is a frequently occurring condition in urologic patients, and the authors proposed that MS evaluation should be part of the standard assessment of male patients with LUTS as well as a new domain in clinical and basic research.
At this time, it is reasonable to suggest that patients with LUTS and MS should exercise regularly, eat a balanced diet, and maintain a healthy weight to prevent or reverse MS. Whether or not this advice will improve patients’ LUTS and progression of benign prostatic enlargement is still a matter or debate, although it will certainly improve heart health and reduce the risk of cardiovascular disease, the most common cause of male mortality. In our opinion, the truly important questions arising from this study are whether the presence of MS should change LUTS assessment and treatment and what the different factors of MS are, such as patient lifestyle including physical activity, abdominal obesity, and multiple serum hormone alterations including testosterone and insulin resistance, that are responsible for the observed association between LUTS and MS. In summary, we would like to accelerate further research on this topic to explore the complex relationship between LUTS and MS.
Pashootan P, Ploussard G, Cocaul A, de Gouvello A, Desgrandchamps F
BJU Int. In press. http://dx.doi.org/10.1111/bju.12931
Experts’ summary:
Pashootan et al, in an observational study, evaluated the relationship between metabolic syndrome (MS) and lower urinary tract symptoms (LUTS) in a large cohort of men aged >55 yr in France. Overall, 4666 male patients were enrolled by 379 general practitioners randomly selected in France. LUTS were evaluated using the International Prostatic Symptoms Score (IPSS), and the Adult Treatment Panel III criteria were used to define the presence of MS. The presence of MS was significantly associated with LUTS severity in terms of overall IPSS (odds ratio [OR]: 1.56; 95% confidence interval [CI], 1.35–1.80;p < 0.001). Voiding and storage scores were increased by 67% and 72%, respectively, in men with MS compared with controls. The risk of being treated for LUTS depended on the number of individual MS components. An OR of 1.5 or 3.5 was observed when 2 or 5 components, respectively, were present (p < 0.001).
Experts’ comments:
MS describes the combination of several metabolic abnormalities and is directly associated with an increase in the risk of coronary heart disease. Recently, epidemiologic and clinical studies in American and Asian populations have provided emerging evidence of a possible role for MS and its components in the occurrence and progression of LUTS[1] and [2]. In Europe, we recently observed that MS is a frequently occurring (24%) condition in patients with LUTS, and its presence increased the risk of having an IPSS storage subscore ≥4 in patients with LUTS by about 80% (OR: 1.78; 95% CI, 1.045–3.042;p = 0.03) [3] . Although the study presented by Pashootan et al confirmed these observations in Western Europe and further increased the evidence of the relationship between MS and LUTS, the study did not investigate the biological mechanism beyond this association. This study also established in a real-life setting that MS is a frequently occurring condition in urologic patients, and the authors proposed that MS evaluation should be part of the standard assessment of male patients with LUTS as well as a new domain in clinical and basic research.
At this time, it is reasonable to suggest that patients with LUTS and MS should exercise regularly, eat a balanced diet, and maintain a healthy weight to prevent or reverse MS. Whether or not this advice will improve patients’ LUTS and progression of benign prostatic enlargement is still a matter or debate, although it will certainly improve heart health and reduce the risk of cardiovascular disease, the most common cause of male mortality. In our opinion, the truly important questions arising from this study are whether the presence of MS should change LUTS assessment and treatment and what the different factors of MS are, such as patient lifestyle including physical activity, abdominal obesity, and multiple serum hormone alterations including testosterone and insulin resistance, that are responsible for the observed association between LUTS and MS. In summary, we would like to accelerate further research on this topic to explore the complex relationship between LUTS and MS.
Pashootan P, Ploussard G, Cocaul A, de Gouvello A, Desgrandchamps F
BJU Int. In press. http://dx.doi.org/10.1111/bju.12931
Experts’ summary:
Pashootan et al, in an observational study, evaluated the relationship between metabolic syndrome (MS) and lower urinary tract symptoms (LUTS) in a large cohort of men aged >55 yr in France. Overall, 4666 male patients were enrolled by 379 general practitioners randomly selected in France. LUTS were evaluated using the International Prostatic Symptoms Score (IPSS), and the Adult Treatment Panel III criteria were used to define the presence of MS. The presence of MS was significantly associated with LUTS severity in terms of overall IPSS (odds ratio [OR]: 1.56; 95% confidence interval [CI], 1.35–1.80;p < 0.001). Voiding and storage scores were increased by 67% and 72%, respectively, in men with MS compared with controls. The risk of being treated for LUTS depended on the number of individual MS components. An OR of 1.5 or 3.5 was observed when 2 or 5 components, respectively, were present (p < 0.001).
Experts’ comments:
MS describes the combination of several metabolic abnormalities and is directly associated with an increase in the risk of coronary heart disease. Recently, epidemiologic and clinical studies in American and Asian populations have provided emerging evidence of a possible role for MS and its components in the occurrence and progression of LUTS[1] and [2]. In Europe, we recently observed that MS is a frequently occurring (24%) condition in patients with LUTS, and its presence increased the risk of having an IPSS storage subscore ≥4 in patients with LUTS by about 80% (OR: 1.78; 95% CI, 1.045–3.042;p = 0.03) [3] . Although the study presented by Pashootan et al confirmed these observations in Western Europe and further increased the evidence of the relationship between MS and LUTS, the study did not investigate the biological mechanism beyond this association. This study also established in a real-life setting that MS is a frequently occurring condition in urologic patients, and the authors proposed that MS evaluation should be part of the standard assessment of male patients with LUTS as well as a new domain in clinical and basic research.
At this time, it is reasonable to suggest that patients with LUTS and MS should exercise regularly, eat a balanced diet, and maintain a healthy weight to prevent or reverse MS. Whether or not this advice will improve patients’ LUTS and progression of benign prostatic enlargement is still a matter or debate, although it will certainly improve heart health and reduce the risk of cardiovascular disease, the most common cause of male mortality. In our opinion, the truly important questions arising from this study are whether the presence of MS should change LUTS assessment and treatment and what the different factors of MS are, such as patient lifestyle including physical activity, abdominal obesity, and multiple serum hormone alterations including testosterone and insulin resistance, that are responsible for the observed association between LUTS and MS. In summary, we would like to accelerate further research on this topic to explore the complex relationship between LUTS and MS.
Pashootan P, Ploussard G, Cocaul A, de Gouvello A, Desgrandchamps F
BJU Int. In press. http://dx.doi.org/10.1111/bju.12931
Experts’ summary:
Pashootan et al, in an observational study, evaluated the relationship between metabolic syndrome (MS) and lower urinary tract symptoms (LUTS) in a large cohort of men aged >55 yr in France. Overall, 4666 male patients were enrolled by 379 general practitioners randomly selected in France. LUTS were evaluated using the International Prostatic Symptoms Score (IPSS), and the Adult Treatment Panel III criteria were used to define the presence of MS. The presence of MS was significantly associated with LUTS severity in terms of overall IPSS (odds ratio [OR]: 1.56; 95% confidence interval [CI], 1.35–1.80;p < 0.001). Voiding and storage scores were increased by 67% and 72%, respectively, in men with MS compared with controls. The risk of being treated for LUTS depended on the number of individual MS components. An OR of 1.5 or 3.5 was observed when 2 or 5 components, respectively, were present (p < 0.001).
Experts’ comments:
MS describes the combination of several metabolic abnormalities and is directly associated with an increase in the risk of coronary heart disease. Recently, epidemiologic and clinical studies in American and Asian populations have provided emerging evidence of a possible role for MS and its components in the occurrence and progression of LUTS[1] and [2]. In Europe, we recently observed that MS is a frequently occurring (24%) condition in patients with LUTS, and its presence increased the risk of having an IPSS storage subscore ≥4 in patients with LUTS by about 80% (OR: 1.78; 95% CI, 1.045–3.042;p = 0.03) [3] . Although the study presented by Pashootan et al confirmed these observations in Western Europe and further increased the evidence of the relationship between MS and LUTS, the study did not investigate the biological mechanism beyond this association. This study also established in a real-life setting that MS is a frequently occurring condition in urologic patients, and the authors proposed that MS evaluation should be part of the standard assessment of male patients with LUTS as well as a new domain in clinical and basic research.
At this time, it is reasonable to suggest that patients with LUTS and MS should exercise regularly, eat a balanced diet, and maintain a healthy weight to prevent or reverse MS. Whether or not this advice will improve patients’ LUTS and progression of benign prostatic enlargement is still a matter or debate, although it will certainly improve heart health and reduce the risk of cardiovascular disease, the most common cause of male mortality. In our opinion, the truly important questions arising from this study are whether the presence of MS should change LUTS assessment and treatment and what the different factors of MS are, such as patient lifestyle including physical activity, abdominal obesity, and multiple serum hormone alterations including testosterone and insulin resistance, that are responsible for the observed association between LUTS and MS. In summary, we would like to accelerate further research on this topic to explore the complex relationship between LUTS and MS.
